NCT02650804View on ClinicalTrials.gov

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 6, 2016

Primary Completion Date

June 11, 2019

Study Completion Date

June 11, 2019

Conditions
Pancreatic Cancer
Interventions
DRUG

BPM31510 Nanosuspension Injection

DRUG

Gemcitabine

Trial Locations (12)

18015

Vita Medical Associates, P.C., Bethlehem

53226

Medical College of Wisconsin, Milwaukee

75230

Mary Crowley Cancer Research Center, Dallas

85234

Banner Health, Gilbert

90403

Sarcoma Oncology Research Center, Santa Monica

95020

Global Cancer Research Institute, Inc., Gilroy

85259-5499

Mayo Clinic, Phoenix

02215

Beth Israel Deaconess Medical Center, Boston

07962

Atlantic Health System Morristown Medical Center, Morristown

G12 0YN

The Beatson West of Scotland Cancer Centre, Glasgow

EC1A 7BE

St Bartholomew's Hospital, London

NW3 2PF

Royal Free London NHS Foundation Trust, London

All Listed Sponsors
lead

BPGbio

INDUSTRY

NCT02650804 - BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter